GHGilad Horowitz

Gilad Horowitz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gilad Horowitz has a total of 84 co-authors. Here are the top co-authors by number of shared publications:

  • Anton Warshavsky

    Gray Faculty of Medical and Health Sciences Tel Aviv University Tel Aviv Israel

    9 shared publications
  • Dan M. Fliss

    Tel Aviv Sourasky Med Ctr, Dept Otolaryngol Head & Neck Surg, IL-64239 Tel Aviv, Israel

    9 shared publications
  • Narin Nard Carmel Neiderman

    Department of Otolaryngology, Head and Neck & Maxillofacial Surgery, Tel Aviv Sourasky Medical Center. Tel Aviv, Israel, affiliated with the Gray Faculty of Medical and Health Sciences, Tel Aviv University

    9 shared publications
  • Nidal Muhanna

    The Department of Otolaryngology, Head & Neck Surgery and Maxillofacial Surgery School of Medicine, Tel‐Aviv University Tel‐Aviv Israel

    5 shared publications
  • Nidal Muhanna

    Department of Otolaryngology, Head and Neck and Maxillofacial Surgery, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    4 shared publications
  • Roni Rosen

    Tel Aviv Sourasky Med Ctr, Dept Otolaryngol Head & Neck Surg, IL-64239 Tel Aviv, Israel

    4 shared publications

Latest Publications

  • Open Access

    Outcomes of Surgical Bed Versus Tumor Margins in Trans-Oral Resection of Early Glottic Cancer

    by Tom Jacob, Narin Nard Carmel Neiderman, Yotam Lior, Anton Warshavsky, Gilad Horowitz, Oshri Wasserzug, Leonore Trejo, Nidal Muhanna, Yael Oestreicher-Kedem

    To assess which margin status, surgical bed margin (SBM) or tumor margin (TM) correlates best with outcome following transoral laser microsurgery (TLM) for early (Tis-T2N0M0) glottic cancer. A retrospective cohort study including patients with early (T1-2) glottic cancer. Data on TM status, SBM status, recurrence rate, and disease-free survival (DFS) were retrieved from the medical records of all patients who underwent vocal fold (VF) cordectomy due to Tis-T2N0M0 glottic squamous cell carcinoma from January 2013 to February 2021. Only patients with available data on both SBM and TM status were included in the study. Forty patients, 34 (85%) with disease-free SBM and TM, and 6 (15%) with disease-free SBM but involved TM, were included. Four (10%) patients developed recurrence, all in the group of both disease-free SBM and TM. The recurrence, 2-year disease free survival and survival at the end of follow-up (median 37.5 months) rates were 11%, 94.1% and 97.1% and 0%, 100% and 100%, in the groups of disease-free SBM and TM and disease-free SBM but involved TM, respectively. There were no statistically significant group differences. TM involvement, in the presence of disease-free SBM, did not compromise outcome.

  • Open Access

    Mutated TP53 in Circulating Tumor DNA as a Risk Level Biomarker in Head and Neck Squamous Cell Carcinoma Patients

    by Liyona Kampel, Sara Feldstein, Shlomo Tsuriel, Victoria Hannes, Narin N. Carmel Neiderman, Gilad Horowitz, Anton Warshavsky, Leonor Leider-Trejo, Dov Hershkovitz, Nidal Muhanna

    Circulating tumor DNA (ctDNA) has been suggested as a surrogate biomarker for early detection of cancer recurrence. We aimed to explore the utility of ctDNA as a noninvasive prognostic biomarker in newly diagnosed head and neck squamous cell carcinoma (HNSCC) patients. Seventy HNSCC specimens were analysed for the detection of TP53 genetic alterations utilizing next-generation sequencing (NGS). TP53 mutations were revealed in 55 (79%). Upon detection of a significant TP53 mutation, circulating cell-free DNA was scrutinized for the presence of the tumor-specific mutation. ctDNA was identified at a minimal allele frequency of 0.08% in 21 out of 30 processed plasma samples. Detectable ctDNA correlated with regional spread (N stage ≥ 1, p = 0.011) and poorer 5-year progression-free survival (20%, 95% CI 10.9 to 28.9, p = 0.034). The high-risk worst pattern of invasion (WPOI grade 4–5) and deep invasion were frequently found in patients whose ctDNA was detected (p = 0.087 and p = 0.072, respectively). Detecting mutated TP53 ctDNA was associated with poor progression-free survival and regional metastases, indicating its potential role as a prognostic biomarker. However, ctDNA detectability in early-stage disease and the mechanisms modulating its release into the bloodstream must be further elucidated.


  • Open Access

    The Prognostic Value and Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test in Cutaneous Squamous Cell Carcinoma: Systematic Review and Meta-Analysis

    by Razan Masarwy, Shahaf Shilo, Narin Nard Carmel Neiderman, Liyona Kampel, Gilad Horowitz, Nidal Muhanna, Jobran Mansour

    Background: The current tumor staging systems for cutaneous squamous cell carcinoma (cSCC) are considered inadequate and insufficient for evaluating the risk of metastasis and for identifying patients at high risk of cSCC. This meta-analysis aimed to assess the prognostic significance of a 40-gene expression profile (40-GEP) both independently and integrated with clinicopathologic risk factors and established staging systems (American Joint Committee on Cancer, eighth edition (AJCC8) and Brigham and Women’s Hospital (BWH)). Methods: Electronic databases, including PubMed (MEDLINE), Embase, the Cochrane Library, and Google Scholar, were systematically searched to identify cohort studies and randomized controlled trials on evaluations of the prediction value of 40-GEP in cSCC patients up to January 2023. The metastatic risk analysis of a given 40-GEP class combined with tumor stage and/or other clinicopathologic risk factors was based upon log hazard ratios (HRs) and their standard error (SE). Heterogeneity and subgroup analyses were performed, and data quality was assessed. Results: A total of 1019 patients from three cohort studies were included in this meta-analysis. The overall three-year metastatic-free survival rates were 92.4%, 78.9%, and 45.4% for class 1 (low risk), class 2A (Intermediate risk), and class 2B (high risk) 40-GEP, respectively, indicating a significant variation in survival rates between the risk classification groups. The pooled positive predictive value was significantly higher in class 2B when compared to AJCC8 or BWH. The subgroup analyses demonstrated significant superiority of integrating 40-GEP with clinicopathologic risk factors or AJCC8/BWH, especially for class 2B patients. Conclusions: The integration of 40-GEP with staging systems can improve the identification of cSCC patients at high risk of metastasis, potentially leading to improved care and outcomes, especially in the high-risk class 2B group.


  • Pre‐resection Intraoperative Core Biopsies in Oral Tongue Cancer—A Pilot Study

    by Anton Warshavsky, Alexandra Dorman, Narin Nard Carmel‐Neiderman, Leonora Leider‐Trejo, Nidal Muhanna, Liyona Kampel, Clariel Ianculovici, Gilad Horowitz


    • 1 February 2022
      • Vol. 24  (2) , 85-88

    Accuracy of Pathology Reports on Neck Dissection Specimens: A Retrospective Case Series Study

    by Anton Warshavsky, Roni Rosen, Uri Neuman, Narin Nard-Carmel, Udi Shapira, Leonor Trejo, Dan M. Fliss, Gilad Horowitz

    Background: Accuracy of the number and location of pathological lymph nodes (LNs) in the pathology report of a neck dissection (ND) is of vital importance. Objectives: To quantify the error rate in reporting the location and number of pathologic LNs in ND specimens. Methods: All patients who had undergone a formal ND that included at least neck level 1 for a clinical N1 disease between January 2010 and December 2017 were included in the study. The error rate of the pathology reports was determined by various means: comparing preoperative imaging and pathological report, reporting a disproportionate LN distribution between the different neck levels, and determining an erroneous location of the submandibular gland (SMG) in the pathology report. Since the SMG must be anatomically located in neck level 1, any mistake in reporting it was considered a categorical error. Results: A total of 227 NDs met the inclusion criteria and were included in the study. The study included 128 patients who had undergone a dissection at levels 1-3, 68 at levels 1-4, and 31 at levels 1-5. The best Kappa score for correlation between preoperative imaging and final pathology was 0.50. There were nine cases (3.9%) of a disproportionate LN distribution in the various levels. The SMG was inaccurately reported outside neck level 1 in 17 cases (7.5%). Conclusions: At least 7.5% of ND reports were inaccurate in this investigation. The treating physician should be alert to red flags in the pathological report.


  • Achieving negative resection margins in oral cavity cancer with masticator space involvement—Is it feasible? International collaborative study

    by Gilad Horowitz, John R. De Almeida, Ilyes Berania, David P. Goldstein, Hugo Fontan Köhler, Luiz Paulo Kowalski, Leandro Luongo Matos, Adi Brenner‐Ullman, Dan M. Fliss, Nidal Muhanna, et al.

    Background Masticator space involvement in oral cavity squamous cell carcinoma (OCSCC) is considered an unresectable disease. Nevertheless, achieving negative resection margins is feasible in limited masticatory space involvement. Materials and Methods A multi-institutional study on OCSCC patients with masticator space invasion who underwent surgical resection. Margin status was assessed according to anatomic tumor involvement of the inframandibular and supra-mandibular notch. Results One-hundred and thirty-two patients met the inclusion criteria. Then, 67 patients (50.8%) were diagnosed with a supra-notch tumor and 65 (49.2%) with an infra-notch disease. Negative margins were more common in the infra-notch group (43.3 vs. 23.1%, p = 0.014), and positive margins were more common in the supra-notch group (41.5 vs. 23.9%, p = 0.041). Multivariable analysis demonstrated that supra-notch tumors had an increased likelihood for involved resection margins (odds ratio = 2.46, p = 0.036). Conclusion OCSCC patients with masticator space involvement are prone for positive surgical margins in tumors extending above the supra-mandibular notch.


  • Outcomes of Tracheal Resections in Well‐Differentiated Thyroid Cancer—A case series and meta‐analysis

    by Anton Warshavsky, Roni Rosen, Narin Nard‐Carmel, Nidal Muhanna, Omer Ungar, Avraham Abergel, Dan M. Fliss, Gilad Horowitz

    Background: Tracheal invasion in thyroid cancer is a well‐known form of advanced disease. There is an ongoing controversy over outcomes of tracheal shaving in this situation. The aim of this study was to compare the results of tracheal shaving to radical resections in patients with low‐volume tracheal involvement.Methods: An institutional case series and a meta‐analysis was conducted. All studies that included patients diagnosed with well‐differentiated thyroid cancer (WDTC) and tracheal invasion were analyzed. Patients with low‐volume tracheal invasion (according to the Shin classification) were extracted from the various studies and subsequently included in this study. The outcomes of tracheal shaving and radical resection were consolidated and compared. All recurrences and mortality over 10 years of follow‐up were calculated using the Kaplan–Meier method.Results: Institutional case series included 22 patients diagnosed with WDTC and tracheal invasion that underwent resection. There was one case of recurrence (4.5%) during the follow‐up period and no mortality. The meta‐analysis yielded a total of 284 patients from six studies who met the inclusion criteria. The 10‐year overall survival was 82.4% for the shave group and 80.8% for the resection group. The combined Kaplan–Meier curves revealed no statistically significant difference between the two techniques (hazard ratio [HR] = 0.86, P = .768). The combined 10‐year local control rate of the shave group was 90.2%.Conclusions: The outcomes of tracheal shaving in low‐volume invasion are similar to more aggressive forms of tracheal resections. Shave resection is oncologically safe in carefully selected WDTC patients demonstrating minimal tracheal invasion.


  • The Actual Incidence and Types of Hearing Losses in Bullous Myringitis: Case Series and Systematic Review

    by Omer J. Ungar, Ophir Handzel, Yahav Oron, Rani Abu Eta, Nidal Muhanna, Anton Warshavsky, Gilad Horowitz, Liam Simani

    Objective: To calculate the incidence of sensorineural hearing loss (SNHL; pure or as part of a mixed hearing loss, MHL) among bullous myringitis (BM) patients with a coexisting HL to assess whether steroidal treatment should be initiated even before the findings of a formal audiogram are available. Methods: Retrospective medical record review in a tertiary referral center and systematic review of the English literature. Results: The medical records of 81 patients with BM were retrieved among whom 50 patients (62%) had actually sustained a HL, although only 39/81 patients reported a HL when asked. Twenty-four patients had a MHL, 18 had a SNHL, and eight had a conductive HL (CHL). The systematic review included 106 ears: 17 had no HL, 53 had a MHL, 20 had a SNHL, and 16 had a CHL. The combined published and current results yielded a SNHL and MHL rates of 38/139 (27%) and 77/139 (55%), respectively of all BM patients with confirmed HL. Conclusion: BM is intuitively associated with a CHL resulting from the impeded function of the affected middle ear. Medical history and physical examination are not sufficient to exclude a SNHL in BM patients, and formal audiometry is mandatory for exclusion/confirmation in this setting. Nevertheless, steroidal treatment should not be delayed until the performance of formal audiometry because the actual rate of pure CHL in this setting is very low. Level of Evidence: 2


  • Thyroid function control among pregnant women following a therapeutic thyroidectomy

    by Gilad Horowitz, Maya Ish‐Shalom, Anton Warshavsky, Naftali Stern, Dan M. Fliss, Doron Comaneshter, Shlomo Vinker

    The total number of thyroidectomies performed for both benign and malignant disease has dramatically increased throughout the past few decades, with females far outnumbering males, and younger patients (1‐3 During pregnancy, a woman’s thyroid physiology undergoes well‐defined changes,4,5 resulting in a significant increase in the total thyroxine pool, primarily during the first trimester.6 Since the pregnant woman is the sole source for fetal supply of thyroid hormones from conception to approximately 13 weeks of gestation, the fetuses of women who had undergone therapeutic total thyroidectomy rely on exogenous thyroxine.


  • Prophylactic central neck dissection has no advantage in patients with metastatic papillary thyroid cancer to the lateral neck

    by Narin N. Carmel‐Neiderman, Aviram Mizrachi, Dan Yaniv, Igor Vainer, Nidal Muhanna, Avraham Abergel, Elena Izhakov, Eyal Robenshtok, Anton Warshavsky, Barak Ringel, et al.

    Background: Papillary thyroid cancer (PTC) usually metastasizes via lymphatic channels in a sequential fashion, first to the central compartment, followed by the lateral neck. PTC patients diagnosed with lateral neck disease (N1b) without proof for central involvement traditionally undergo prophylactic central neck dissection (pCND). However, substantial evidence on outcomes to support this approach is lacking.Materials and Methods: We conducted a dual center retrospective study to compare the rate of central neck recurrence between N1b PTC patients undergoing pCND and those spared pCND. All patients diagnosed with N1b PTC who underwent total thyroidectomy and lateral neck dissections with or without pCND between January 1998 and December 2015 were included in this study. The rates of central neck recurrences were compared between the groups.Results: The 111 patients who met the inclusion criteria were 44 females (39.6%) and 67 males (60.4%), with a mean age of 50.2 ± 17.7 years, and a mean follow‐up of 10.2 ± 5.3 years. Sixty patients (54.1%) underwent a pCND and 51 patients (45.9%) did not (non‐pCND). During follow‐up, 18 patients (16.2%) had level VI recurrences, 13 in the pCND group and 5 in the non‐pCND group. Cox‐regression models with propensity scoring did not reveal any inclination or an advantage for performing pCND.Conclusion: The present study demonstrated no advantage in performing pCND to prevent central neck recurrence among PTC patients with lateral neck involvement only. These findings question the need for pCND in patients without clinical evidence of central neck disease.